ERYTECH Pharma

ERYTECH Pharma est membre de Lyonbiopôle

General information

Batiment Adénine, 60 avenue Rockefeller

69008 LYON

Incorporated in: 2004/11/15

Number of employees: 113


More information

 

Main activity

Founded in 2004, Erytech is a biopharmaceutical company developing innovative therapies to target unmet medical needs, particularly in the fields of cancer and orphan diseases. Erytech’s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. Encapsulation offers a number of benefits as compared to free-form compounds, reducing the potential for allergic reactions and allowing the therapeutic substance to remain longer in the body. Its first product, working by starving tumors, has completed its phase III development and will provide a therapeutic solution to patients with relapsed and refractory acute lymphoblastic leukemia. The company has a production unit located in Lyon with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements, with Orphan Europe-Recordati (in Europe) and TEVA (in Israel).  


Funding

Looking for funding: Yes

Nature of funding searches: Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs http://erytech.com/pipeline.html    

Private funding obtained: June 2006 : 12 Millions Euros ; June 2010 : 5.2 Millions Euros ; April 2013 : 17.7 Millions Euros (IPO) ; October 2014 : 30 Millions Euros December 2015 : 25.4 Millions Euros December 2016 : 9.9 Millions Euros April 2017 : 70 Millions Euros November 2017 : 144 Millions US Dollars (IPO)

Public funding obtained: 2008: 600 k€ / subsidy ; 2009: 767 k€ / sub ; 215 k€ / repayable advance ; 2010: 77 k€ / sub ; 2011: Oseo:   2 M€:sub / 5  M€ : repayable advance  

Stock exchange listing: 30/04/2013: IPO in compartment C of the NYSE Euronext regulated market in Paris (17.7 Millions Euros) 10/11/2017 : IPO in US Nasdaq Global Select Market (144 Millions US Dollars)

Segmentation
Activities
Products / Services / Technologies
Partnership opportunities / Licensing

Strategic area of application
Human Medicine


Application market
Immune, AutoIm & Inflam. diseases - Oncology - Metabolic Diseases


Activities
Therapeutics, Pharma or Biotech


Technologies
Cell Therapy - cell biology - Biobanking - Drug delivery device - services - Antibodies - Protein - Peptide

En poursuivant votre navigation sur ce site, vous acceptez l'utilisation de cookies pour vous proposer des services et offres adaptés à vos centres d'intérêt. En savoir plus... Fermer